Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
Price:
8.12 USD
-2.17%
Market Closed
Updated:
May 5, 2024
Ironwood Pharmaceuticals Inc
Operating Income
|
Ironwood Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
|
Operating Income
$168.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is Ironwood Pharmaceuticals Inc's Operating Income?
Operating Income
168.3m
USD
168.3m
USD
Based on the financial report for Dec 31, 2023, Ironwood Pharmaceuticals Inc's Operating Income amounts to 168.3m USD.
What is Ironwood Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
65%
65%
Over the last year, the Operating Income growth was -33%. The average annual Operating Income growth rates for Ironwood Pharmaceuticals Inc have been 2% over the past three years , 65% over the past five years .
You don't have any saved screeners yet
